**CASE REPORT**

A novel case with germline p53 gene mutation having concurrent multiple primary colon tumours

M Miyaki, T Iijima, M Ohue, Y Kita, T Hishima, T Kuroki, T Iwama, T Mori

During a search for causative genes in patients with concurrent multiple primary colon tumours, we found a novel case with a germline mutation of the p53 gene, from GCC (Ala) to GTC (Val) at codon 189. Of the six primary colon tumours that this patient had, one large advanced carcinoma exhibited a somatic p53 mutation and a somatic APC mutation, in addition to the germline p53 mutation. Two early carcinomas and three adenomas had somatic APC mutations but no somatic p53 mutation or loss of the p53 allele. K-ras-2 mutations were detected in an advanced carcinoma and an early carcinoma. The present results suggest that a patient with a certain type of germline p53 mutation is predisposed to concurrent multiple colon tumours. It is also suggested that in such a patient, a somatic APC mutation is involved in tumour formation and that an additional somatic p53 mutation contributes to tumour progression.

The number of carcinomas ranged from 1 to 5 and polyps from 1 to 7. All tumours exhibited no microsatellite instability. Of these patients, a 73 year old man (COK169) was referred to the Tokyo Metropolitan Komagome Hospital because of lower right abdominal pain. Barium enema examination showed the existence of a large tumour between the caecum and ascending colon, and polyps in the ascending colon. No personal history or obvious family history of tumours was known. Neither of his parents nor any of his three brothers were affected by tumours. A right hemicolectomy was performed. Although colon carcinoma did not recur, he died six years later as a result of squamous cell carcinoma of the lung. He was a non-smoker. Pathological diagnosis of the resected colon showed that the large colon tumour, located at the caecum, was an advanced carcinoma with an ulcerative carcinomatous lesion (Ca in fig 1). The histological type of this carcinoma was a well to moderately differentiated adenocarcinoma invading the subserosa. Dukes' classification for this carcinoma was B. Moreover, there were five polyps, including two early carcinomas and three adenomas of the ascending colon. Both of the early carcinomas (P1 and P2 in fig 1) were diagnosed as well differentiated intramucosal adenocarcinomas. The three adenomas (P3, P4, and P5 in fig 1) were diagnosed as tubular adenomas, with severe atypia. Neoplastic cells comprised approximately 70% of the total cells in each tumour sample, which was assessed by haematoxylin-eosin staining of formalin fixed paraffin embedded sections. Appropriate areas of tumour tissues were frozen at −80°C until they were used for mutation analysis.

DNA was extracted from these tumours and normal mucosa. Mutations of the p53, APC, and K-ras-2 genes in DNA samples were analysed by polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) using

**Figure 1** Resected colon from patient COK169. There was one advanced carcinoma (Ca) and five polyps (P1–P5).

**CASE REPORT**

Fifteen patients without germline mutations of the APC and mismatch repair genes were examined after approval by the Komagome Hospital Review Committee. Each of the 15 patients had both colorectal carcinomas and colorectal polyps.
Microsatellite instability was analysed by PCR using BAT26, BAT40, D5S346, D2S123, and TP53 as primers. Instability was revealed as abnormal bands on PCR-SSCP gels. Direct sequencing of DNA fragments from these abnormal bands revealed no mutant band having these two mutations—that is, all mutant bands analysed showed only one of the two mutations (data not shown). These results support the idea that germline and somatic p53 mutations occur in different alleles of the p53 gene. Other tumours (P1–P5) also had a germline p53 mutation but exhibited no somatic p53 mutation or loss of the p53 allele.

To clarify whether germline and somatic p53 mutations existed on different alleles of the p53 gene, we extracted RNA from COK169Ca and performed reverse transcription-PCR-SSCP analysis using a primer set which amplifies the region, including both germline (at codon 189) and somatic (at codon 245) mutations. SSCP showed multiple mutant bands, and direct sequencing of DNA fragments from these bands revealed no mutant band having these two mutations—that is, all mutant bands analysed showed only one of the two mutations (data not shown). These results support the idea that germline and somatic mutations occur in different alleles of the p53 gene. Other tumours (P1–P5) also had a germline p53 mutation but exhibited no somatic p53 mutation or loss of the p53 allele. Somatic APC mutations were detected in advanced carcinoma (Ca), two early carcinomas (P1, P2), and three adenomas (P3, P4, P5). All APC mutations were located at the central region of the APC gene and resulted in stop codons. K-ras–2 mutations were detected in the advanced carcinoma (Ca) and in one of the two early carcinomas (P1).

Microsatellite instability was analysed by PCR using BAT26, BAT40, D5S346, D2S123, and TP53 as primers. Instability was not observed in any tumour. These data are summarised in Table 1.

**Table 1** Genetic changes detected in concurrent multiple colon tumours from patient COK169

<table>
<thead>
<tr>
<th>Tumour</th>
<th>Size (mm)</th>
<th>Pathological diagnosis</th>
<th>Germline p53 mutation</th>
<th>Somatic p53 mutation</th>
<th>Somatic APC mutation</th>
<th>Somatic K-ras mutation</th>
</tr>
</thead>
<tbody>
<tr>
<td>COK169 Ca</td>
<td>82×40</td>
<td>Advanced carcinoma</td>
<td>189 GCC→GTC</td>
<td>245 GGC→AGC</td>
<td>1487→8 T deletion</td>
<td>135 GGC→GAC</td>
</tr>
<tr>
<td>COK169 P1</td>
<td>12×10×6</td>
<td>Early carcinoma</td>
<td>189 GCC→GTC</td>
<td>—</td>
<td>1545 TCA→TGA</td>
<td>—</td>
</tr>
<tr>
<td>COK169 P2</td>
<td>11×7×3</td>
<td>Early carcinoma</td>
<td>189 GCC→GTC</td>
<td>—</td>
<td>1378 CAG→TAG</td>
<td>12 GGT→GTT</td>
</tr>
<tr>
<td>COK169 P3</td>
<td>6×3×2</td>
<td>Adenoma with severe atypia</td>
<td>189 GCC→GTC</td>
<td>—</td>
<td>1449→75 80 bp repeat</td>
<td>—</td>
</tr>
<tr>
<td>COK169 P4</td>
<td>3×2×1</td>
<td>Adenoma with severe atypia</td>
<td>189 GCC→GTC</td>
<td>—</td>
<td>1450 CGA→TGA</td>
<td>—</td>
</tr>
<tr>
<td>COK169 P5</td>
<td>3×2×1</td>
<td>Adenoma with severe atypia</td>
<td>189 GCC→GTC</td>
<td>—</td>
<td>1367 CAG→TAG</td>
<td>—</td>
</tr>
</tbody>
</table>

—, Mutation was not detected

**Discussion**

We found a novel case with concurrent multiple primary colon tumours who had a germline p53 mutation from GCC (Ala) to GTC (Val) at codon 189. A somatic p53 mutation has been detected at high frequency (nearly 50%) in colon carcinomas from sporadic and FAP patients, but a germline p53 mutation has not been described in association with colon carcinomas. A germline p53 mutation is usually associated with LF syndrome which is characterized by a family history of various malignant tumours. Patients with typical LF syndrome develop sarcomas at a young age, often in childhood, breast cancers and brain tumours at younger than 44 years, and often form various multiple tumours. However, colorectal cancer is rare in this syndrome, and onset is at a rather later age (older than 44 years). Although the present case was old (aged 73 years), he may be an LF-like patient as he had multiple colon tumours and died later of cancer in another organ. He may carry a new germline mutation as no obvious family history of cancer was observed. The reason why colon carcinomas occurred at such a late age is difficult to understand. Mis-sense mutation-type p53 protein is assumed to form a complex with the wild-type p53 protein resulting in inactivation of the wild-type protein (dominant-negative effect). One explanation for the occurrence of colon carcinomas at a late age may be that such a dominant-negative effect of the mutation at codon 189 is weak compared with other typical germline p53 mutations. The effect of an unknown modifier gene(s) is also possible.

It is important to determine whether the germline mutation is pathogenic or a rare polymorphism. More than 140 germline p53 mutations have been reported, and the p53 gene has polymorphisms at more than six codons. Germline mutation at codon 189, GCC (Ala) to GTC (Val), has not previously been described, and this mutation may not be a polymorphism as it was not detected in 155 individuals without colorectal cancer in our examination. Codon 189 is located within the L2 loop, which is necessary for binding of p53 protein to the minor groove of DNA. Mutation at codon 189 is assumed to perturb DNA binding ability of p53 protein, and from this aspect this mutation is assumed to be pathogenic. A somatic mutation of the same codon has previously been reported in a colon carcinoma, although the direction of mutation was different, GCC (Ala) to ACC (Thr). By analogy with this somatic mutation, the germline mutation at codon 189 of our patient may also be pathogenic.

With respect to colon carcinogenesis in LF syndrome, the mechanism is still unclear because genetic alterations in colon tumours from this syndrome have not been reported. The present data suggest a contribution of a somatic APC mutation to tumour formation and an additional somatic p53 mutation, possibly in the wild-type allele, to progression from early to advanced carcinoma. Loss of heterozygosity at the p53 locus detected in various tumours from LF patients has been described to be nearly 50%; therefore, some of the remaining cases are assumed to have a somatic p53 mutation in the
wild-type allele, similar to the present advanced colon carcinoma. The somatic K-ras-2 mutation is also involved in some colon tumours. The genetic events observed in the colon tumours in the present LF-like patient are those occurring in the adenoma-carcinoma sequence.21-24 Later onset of colon cancer in LF syndrome may be due to such a mechanism of carcinogenesis which includes contribution of a biallelic somatic APC mutation.

The present results suggest that in searching for causative genes in patients with multiple colon cancer, it is necessary to examine not only APC and mismatch repair genes but also the p53 gene.

ACKNOWLEDGEMENT
This work was supported in part by a Showa University Grant-in-Aid for Innovative Collaborative Research Projects and Special Research Grant-in-Aid for Development of Characteristic Education from the Japanese Ministry of Education, Culture, Sports, Science, and Technology of Japan.

Authors’ affiliations
M Miyaki, T Iijima, Hereditary Tumor Research Project, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan, and Institute of Molecular Oncology, Showa University, Tokyo, Japan
Y Kitoh, Hereditary Tumor Research Project, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan
M Ohue, T Mori, Department of Surgery, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan
T Hishima, Department of Pathology, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan
T Kuruki, Institute of Molecular Oncology, Showa University, Tokyo, Japan
T Iwama, Kyounda Hospital, Sasaki Institute, Tokyo, Japan

Correspondence to: M Miyaki, Hereditary Tumor Research Project, Tokyo Metropolitan Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku Tokyo 113-8677, Japan; mmiyaki@opal.famille.ne.jp

REFERENCES